Laser Red-Light Therapy Delivers Irradiance Levels Exceeding Safety Limits

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

WEDNESDAY, March 11, 2026 -- Laser-based red-light therapy instruments, used for myopia in children, deliver irradiance levels that reach American National Standards Institute (ANSI) safety limits within exposure times before the recommended treatment time, according to a study published online Feb. 5 in JAMA Ophthalmology.

Lisa A. Ostrin, O.D., Ph.D., and Alexander W. Schill, Ph.D., from the University of Houston College of Optometry, examined the optical output and safety classification of four commercially available red-light therapy devices for myopia management using ANSI guidelines. Laboratory-based evaluation of the Sky-n1201, Future Vision, EyeRising, and AirDoc instruments were included in the quality improvement study.

The researchers found that for a 7-mm pupil, the Sky-n1201 and EyeRising devices reached ANSI group 1 limits within exposure times of 2.8 and 1.4 seconds, respectively, and were classified as Class 1 and 2M laser devices, respectively. Group 1 limits were reached by the Future Vision device under extended exposure times of 253 seconds or longer, but did remain within limits for classification of Class 1 laser. Diffuse illumination was produced by the light-emitting diode-based AirDoc, with a time to group 1 limit of 22,761 seconds, classifying it as a group 1 ophthalmic instrument.

"We urge eye care professionals, researchers, and regulatory agencies to prioritize safety assessments of these devices, including adaptive optics retinal imaging, multi-focal electroretinography, and long-term cohort monitoring, before widespread pediatric use," Ostrin said in a statement. "Establishing a balance between therapeutic efficacy and ocular safety remains essential to ensure that this intervention intended to preserve lifelong vision does not itself pose avoidable risks that outweigh benefits."

Ostrin has received consulting fees from Zeiss and Alcon.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-03-12 01:49

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords